Indian Pharma Soars with Record US Generic Drug Profits
Indian pharmaceutical companies are reporting exceptional earnings driven by US generic drug sales, leading to major fundraising initiatives for expansion into medtech and wellness sectors.
Indian pharmaceutical companies are reporting exceptional earnings driven by US generic drug sales, leading to major fundraising initiatives for expansion into medtech and wellness sectors.
British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.
Jairam Sridharan-led Piramal Finance secures strategic foreign investment from Abu Dhabi's International Holding Company and Samman Capital, signaling strong global confidence in India's NBFC sector.
Solara Active Pharma Sciences faces challenging quarter with ₹10 crore net loss despite revenue growth. Discover the operational challenges and management's recovery strategy.
India's pharmaceutical giant Sun Pharma reports steady Q2 growth with 9% revenue increase while navigating US market challenges. Key insights from their latest earnings report.
Discover why Navin Fluorine International shares skyrocketed 22% in just three trading sessions. Expert analysis reveals the key drivers behind this chemical sector powerhouse's impressive rally and what investors should watch next.
Market eyes Wednesday's Q2 earnings bonanza as pharma giant Sun Pharma, Grasim Industries, and FMCG major Britannia declare results. Get complete analysis and investor expectations.
Religare Broking's Ajit Mishra reveals 3 promising stocks for short-term gains. Discover technical analysis and price targets for Grasim, Aurobindo Pharma, and City Union Bank in this exclusive market insight.
Get expert stock market insights from Jigar Patel of Anand Rathi as he reveals why Oil India, Aurobindo Pharma, and Latent View Analytics present compelling short-term opportunities for Indian investors.
Indian biopharmaceutical leader Health Biotech Limited makes waves at CPhI Frankfurt 2025, showcasing innovative products and forging international partnerships to strengthen its global market position.
Chandigarh-based Niner Pharma announces massive R&D expansion with 125 novel peptide molecules targeting wellness and cosmetic innovation, positioning India as global leader in peptide research.
Cipla's stock faced significant pressure after Q2 FY2025 results revealed margin pressures despite revenue growth. Discover the key factors behind the 4% decline and what analysts are saying about the pharmaceutical giant's future prospects.
Federal health officials are accelerating efforts to bring cheaper biotech drugs to market, potentially transforming treatment access and creating new opportunities for Indian pharmaceutical companies.
India implements sweeping regulatory reforms to combat fraudulent pharmaceutical manufacturing licenses, enhancing drug safety standards for domestic and international markets including US and EU.
Discover why prominent investor Mukul Agrawal is betting big on a small-cap pharma company with massive growth potential. Get exclusive insights into his latest portfolio move and what it means for retail investors.
Discover how Dr. Anji Reddy's visionary journey from generics to innovative drug research positioned India as a global pharmaceutical powerhouse and continues to inspire future generations.
In a revolutionary healthcare development, Bangladesh's Beximco Pharma launches affordable generic version of lifesaving rare disease drug, dramatically reducing treatment costs from crores to lakhs for patients across South Asia.
Sigachi Industries faces turbulent quarter with net profit crashing to ₹10.5 crore amid significant revenue decline. What's behind the pharmaceutical giant's disappointing performance?
Cipla's stock faces unexpected pressure despite securing rights to manufacture and distribute Eli Lilly's revolutionary weight loss drug Mounjaro in India. Discover why investors remain cautious.
Indian pharmaceutical giant Cipla announces landmark deal with Eli Lilly to manufacture and distribute popular weight loss medications Mounjaro and Zepbound in India under different brand names.
Indian pharma giant Aurobindo Pharma establishes new subsidiary in Chile, marking strategic expansion across South American markets with focus on branded prescriptions and over-the-counter medicines.
In a major pharmaceutical industry move, Torrent Pharmaceuticals receives Competition Commission of India approval to acquire controlling stake in JB Chemicals & Pharmaceuticals, marking significant consolidation in Indian pharma sector.
A significant legal triumph for India's pharmaceutical sector strengthens the position of generic drug makers against patent challenges. Explore how this ruling impacts affordable medicine production and India's role as the 'Pharmacy of the World'.
Danish pharma giant Novo Nordisk, the company behind diabetes & weight-loss blockbusters Ozempic and Wegovy, announces a major boardroom reshuffle. Get the inside scoop on the new faces and strategic direction.
Meet the trailblazing female entrepreneurs who built healthcare empires from scratch and are reshaping medical innovation worldwide. Discover their inspiring journeys to billions.
Delhi Police uncovers how Nigerian drug cartels are recruiting Indian students from pharma colleges, providing specialized training, and creating sophisticated dispatch systems to smuggle narcotics globally.
Expert analysis compares Zydus Lifesciences and Rubicon Research in the booming Indian pharmaceutical sector. Discover key financial metrics, growth drivers, and investment outlook for these promising stocks.
India's pharmaceutical sector gears up for Q2 FY25 with projected 5-7% revenue growth, navigating US pricing pressures and domestic GST reductions while maintaining stable profitability.
In a major breakthrough, Narcotics Control Bureau uncovers sophisticated drug manufacturing unit in Madhya Pradesh's Ratlam district. Highly educated pharma graduates among those arrested in interstate narcotics operation.